|Bid||5.760 x 0|
|Ask||5.780 x 0|
|Day's Range||5.640 - 5.850|
|52 Week Range||4.770 - 7.000|
|PE Ratio (TTM)||12.32|
|Earnings Date||Mar 20, 2018 - Mar 26, 2018|
|Forward Dividend & Yield||0.11 (1.76%)|
|1y Target Est||6.46|
Companies with shares trading at a market price below what they are actually worth, such as Yuexiu Transport Infrastructure and 361 Degrees International, are deemed undervalued. Smart investors can makeRead More...
March 27 (Reuters) - Shandong Weigao Group Medical Polymer Co Ltd: * RECOMMENDED PAYMENT OF A FINAL DIVIDEND OF RMB0.046 PER SHARE * FY NET PROFIT ATTRIBUTABLE RMB1.34 BILLION, UP 2.3 PERCENT * FY TURNOVER ...
Companies with shares trading at a market price below what they are actually worth, such as Hua Hong Semiconductor and Shandong Weigao Group Medical Polymer, are deemed undervalued. Investors canRead More...
Categories: Yahoo FinanceShandong Weigao Group Medical Polymer Co. Ltd. relative valuation is now OVERVALUED. It was previously rated NEUTRAL, and has a fundamental analysis score of 47. Our analysis is based on comparing Shandong Weigao Group Medical Polymer Co. Ltd. with the following peers – LifeTech Scientific Corporation, PW Medtech Group Ltd., Nanjing Sinolife United Co., Ltd. ... Read more (Read more...)
Dec 4 (Reuters) - Shandong Weigao Group Medical Polymer Co Ltd: * SHANDONG WEIGAO GROUP MEDICAL POLYMER CO - XIA LIE BO HAS RESIGNED AS AN EXECUTIVE DIRECTOR WITH EFFECT FROM 4 DEC 2017 * NIKKISO AGREED ...
Shandong Weigao Group Medical Polymer Co. agreed to buy closely held Argon Medical Devices Inc. for $850 million, continuing a string of deals by Chinese companies seeking to gain a foothold in the U.S. ...
China's Shandong Weigao Group Medical Polymer Co Ltd has agreed to acquire US-based and unlisted Argon Medical Devices Holdings Inc for $850 million, as part of its overseas expansion drive. Weigao Group, mainly engaged in the production and sale of medical devices, orthopaedic and blood purification products, has been seeking opportunities to bolster its product portfolio, the company said in a filing to the Hong Kong Stock Exchange. The company has also been looking to diversify its revenue stream to increase the contribution of sales from overseas markets, and expects "significant growth opportunities" for Argon Medical's products in China.